Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 576 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Is a Genomic Test Better at Finding Aggressive Prostate Cancer? October 13, 2022 EMA Recommends Extension of Indications for Selumetinib October 9, 2025 What Is Pancreatic Enzyme Replacement Therapy in Cancer Care? June 22, 2021 Grabbing the Perfect Gift December 16, 2023 Load more HOT NEWS New on NCI’s Website for July 2023 – Researcher/Trainee Special Edition FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumour EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab ΚΑΡΚΙΝΟΣ ΤΩΝ ΟΣΤΩΝ